Urapidil

This classification denotes an adrenergic alpha-1 receptor antagonist and antihypertensive agent with the molecular formula C20H29N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A78GF17HJS, chemically known as 2,4(1h,3h)-pyrimidinedione, 6-((3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl)amino)-1,3-dimethyl- (9ci) but generally known as urapidil, which bears US NIH Compound Identifier 5639. European Medicines Agency schedules Urapidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11384MIG. World Health Organization schedules urapidil in its Anatomical Therapeutic Chemical (ATC) Classification. URAPIDIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule urapidil under HS 29335995 and SITC 51576. As of Q4 2014, URAPIDIL remains the US FDA Preferred Term for this commodity. SMILES: O(C1C(N2CCN(CC2)CCCNC2N(C(=O)N(C(=O)C2)C)C)CCCC1)C.